Phase 3
Completed N=92
Effects of Stress-reducing Aromatherapy
Stress-related Problems
Source: ClinicalTrials.gov NCT01307748 ↗
Enrolled (actual)
92
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcomePrimary: Percent of Baseline Level of Salivary Cortisol — 170.8; 224.7; 274.7; 106.4 percentage of baseline cortisol level — p=.005
◆ Published Evidence
Established
40citations · ~4 / year
Aroma Effects on Physiologic and Cognitive Function Following Acute Stress: A Mechanism Investigation.
Summary
The study purpose is to evaluate efficacy of stress-reducing aromatherapy and learn about how aromatherapy works.
Linked Publications (2)
-
Aroma Effects on Physiologic and Cognitive Function Following Acute Stress: A Mechanism Investigation.
-
Expectancy of stress-reducing aromatherapy effect and performance on a stress-sensitive cognitive task.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent of Baseline Level of Salivary Cortisol |
170.8; 224.7; 274.7; 106.4; 187.3; 131.2 | .005 sig |
| SECONDARY Electroencephalography (EEG) Frontal Asymmetry |
.013; .006; .036; .005; -.014; .064 | — |
| SECONDARY Cognitive Performance: Percent Change From Baseline in Digit Span Backward Task Score |
15.24; -.37; 0.92 | .01 sig |
Eligibility Criteria
Inclusion Criteria
- in good physical and cognitive health
- reporting moderate level of stress
- able to perceive aromas
- able to understand and follow study instructions
Exclusion Criteria
- taking medications affecting central nervous system (CNS) function or physiologic measures (e.g. steroids or neuroleptics)
- reporting smell sensitivities or allergies
- smoking presently or in the past less than one year prior to enrollment
Data sourced from ClinicalTrials.gov (NCT01307748) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.